GRObio’s groundbreaking science
We have developed the only synthetic biology platform that grants access to the full universe of non-standard amino acids (NSAAs) with novel therapeutic applications.
More About Us
The GRO Platform
The GRO platform removes the barriers historically associated with protein therapeutics.
By granting access to the full universe of non-standard amino acids (NSAAs), the GRO platform overcomes the limitations on potency, immunogenicity, and stability impairing therapeutics constructed from the 20 standard amino acids.
LEARN MORE
ProGly™ Programs
Our programs are focused in two primary areas: reversing autoimmunity and eliminating immunogenicity.
ProGly™ NSAAs are pre-glycosylated amino acids installed by the GRO platform that provide precise control over the glycan composition on any protein. We use this approach to reeducate the immune system to reverse autoimmune processes.
LEARN MORE
Featured Press
GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Proceeds to advance clinical development of lead program for gout, broaden the Company’s pipeline, and expand its genomically recoded organism platform BOSTON, July 19, 2024 - GRO Biosciences Inc. (“GRObio”),…
Read More
GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
BOSTON, March 18, 2024 - GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics,…
Read More
GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies
Data represent promising new modalities for reversing autoimmune disease without immunosuppression and for eliminating anti-drug antibodies against immunogenic therapies BOSTON, September 27, 2023 - GRO Biosciences Inc. (“GRObio”), an emerging…
Read More
